Completed PHASE2/PHASE3 INTERVENTIONAL 6-arm NCT02848326

Efficacy, Safety, and Tolerability of Multiple Dosing Regimens of Oral Atogepant (AGN-241689) in Episodic Migraine Prevention

A Phase 2/3, Multicenter, Randomized, Double-Blind, Placebo Controlled, Parallel-Group Study To Evaluate The Efficacy, Safety, And Tolerability Of Multiple Dosing Regimens Of Oral AGN-241689 In Episodic Migraine Prevention

Sponsor: Allergan

Conditions Migraine, With or Without Aura

Interventions Atogepant Placebo-matching Atogepant

Updated 12 times since 2017 Last updated: Nov 13, 2018 Started: Sep 6, 2016 Primary completion: Apr 2, 2018 Completion: Apr 23, 2018

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This PHASE2/PHASE3 trial investigates Migraine, With or Without Aura and is currently completed. Allergan leads this study, which shows 12 recorded versions since 2016 — indicating substantial longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.

Status Flow

Change History

12 versions recorded

Sep 2025 — Present [monthly]

Completed PHASE2/PHASE3
Sep 2024 — Sep 2025 [monthly]

Completed PHASE2/PHASE3
Jul 2024 — Sep 2024 [monthly]

Completed PHASE2/PHASE3

Phase: PHASE2_PHASE3 → PHASE2/PHASE3
Jan 2021 — Jul 2024 [monthly]

Completed PHASE2_PHASE3
Jan 2019 — Jan 2021 [monthly]

Completed PHASE2_PHASE3

▶ Show 7 earlier versions

Jun 2018 — Jan 2019 [monthly]

Completed PHASE2_PHASE3

Status: Active Not Recruiting → Completed
May 2018 — Jun 2018 [monthly]

Active Not Recruiting PHASE2_PHASE3
Mar 2018 — May 2018 [monthly]

Active Not Recruiting PHASE2_PHASE3

Status: Recruiting → Active Not Recruiting
Feb 2018 — Mar 2018 [monthly]

Recruiting PHASE2_PHASE3
Aug 2017 — Feb 2018 [monthly]

Recruiting PHASE2_PHASE3
Feb 2017 — Aug 2017 [monthly]

Recruiting PHASE2_PHASE3
Jan 2017 — Feb 2017 [monthly]

Recruiting PHASE2_PHASE3

First recorded

Sep 2016

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Allergan

Data source: Allergan

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Allentown, United States , Alpharetta, United States , Amherst, United States , Ann Arbor, United States , Atlanta, United States , Austin, United States , Bellevue, United States , Berlin, United States , Birmingham, United States , Blue Island, United States and 59 more locations